IMMVF Stock UPDATES Immuno Vaccine Inc (IMMVF) 0.6133 08/03/2014
Post# of 273249
Posted On: 08/03/2014 7:13:37 PM
Immuno Vaccine Inc (IMMVF) 0.6133 $IMMVF
Immunovaccine Appoints Marc Mansour as Chief Executive Officer
Marketwire - Wed Jun 11, 8:23AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that Marc Mansour, Ph.D., MBA, has been appointed Chief Executive Officer. Albert Scardino, executive chairman since last year, will return to his role as non-executive chairman of the Company. Dr. Mansour has previously served as the Company's Chief Operating Officer and Chief Science Officer and is a member of its board of directors.
Immunovaccine Reports Promising Clinical Activity for Novel T Cell Activating Immunotherapy DPX-Survivac at ASCO 2014
Marketwire - Thu Jun 05, 1:36AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, presented positive results from a Phase I/Ib clinical study of the Company's lead cancer vaccine candidate, DPX-Survivac, this weekend at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. In a poster presentation at the conference, Immunovaccine highlighted promising early evidence of clinical activity for DPX-Survivac in ovarian cancer patients. One patient, who experienced a 43% reduction in tumor size, was classified as a partial response (PR) as measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1). The PR, which persisted following discontinuation of treatment, was accompanied by reduction in levels of a commonly used ovarian cancer biomarker (CA125) and a significant increase in vaccine-induced immune responses. The patient's tumor and CA125 levels remain stable eight months following initiation of the DPX-Survivac therapy demonstrating a potentially durable effect of the therapy.
Immunovaccine Announces Financial Results for Quarter Ended March 31, 2014
Marketwire - Wed May 28, 4:06PM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" (TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended March 31, 2014.
Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine" (TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex" today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses.
Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Immunovaccine Inc names Dr Llew Keltner to board
M2 - Tue Jan 21, 4:13AM CST
Immunotherapy company Immunovaccine Inc (TSX VENTURE:IMV) reported on Monday the addition of Dr Llew Keltner, MD, PhD to its board of directors with immediate effect.
Llew Keltner, US Biotech Industry Adviser, Joins Board of Immunovaccine
Marketwire - Mon Jan 20, 7:08AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately.
Immunovaccine Grants Stock Options
Marketwire - Mon Jan 20, 7:06AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that pursuant to terms and conditions of the Company's stock option plan, it has granted 1,731,500 stock options to employees, consultants, officers and directors. Employees and consultants were granted an aggregate of 457,500 options and officers and directors were granted an aggregate of 1,274,000 options. The options were granted on January 17, 2014 at an exercise price of $0.74. The options for the employees, consultants and directors will vest in three equal tranches at 6, 12, and 18 months from date of grant and the options for the officers will vest in three equal tranches, the first on the date of grant and the others on the first and second anniversary of the date of grant. All options are set to expire five years from the date of grant.
Immunovaccine to Present at 6th Annual Biotech Showcase Conference
Marketwire - Thu Jan 09, 7:05AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company" (TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at the 6th Annual Biotech Showcase Conference. The conference will take place January 13-15, 2014 at the Parc 55 Wyndham San Francisco Union Square Hotel.
Immunovaccine Appoints Marc Mansour as Chief Executive Officer
Marketwire - Wed Jun 11, 8:23AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that Marc Mansour, Ph.D., MBA, has been appointed Chief Executive Officer. Albert Scardino, executive chairman since last year, will return to his role as non-executive chairman of the Company. Dr. Mansour has previously served as the Company's Chief Operating Officer and Chief Science Officer and is a member of its board of directors. Immunovaccine Reports Promising Clinical Activity for Novel T Cell Activating Immunotherapy DPX-Survivac at ASCO 2014
Marketwire - Thu Jun 05, 1:36AM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX VENTURE: IMV), a clinical stage vaccine company, presented positive results from a Phase I/Ib clinical study of the Company's lead cancer vaccine candidate, DPX-Survivac, this weekend at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. In a poster presentation at the conference, Immunovaccine highlighted promising early evidence of clinical activity for DPX-Survivac in ovarian cancer patients. One patient, who experienced a 43% reduction in tumor size, was classified as a partial response (PR) as measured by Response Evaluation Criteria In Solid Tumors (RECIST 1.1). The PR, which persisted following discontinuation of treatment, was accompanied by reduction in levels of a commonly used ovarian cancer biomarker (CA125) and a significant increase in vaccine-induced immune responses. The patient's tumor and CA125 levels remain stable eight months following initiation of the DPX-Survivac therapy demonstrating a potentially durable effect of the therapy. Immunovaccine Announces Financial Results for Quarter Ended March 31, 2014
Marketwire - Wed May 28, 4:06PM CDT
Immunovaccine Inc. ("Immunovaccine" or "IMV"
(TSX VENTURE: IMV), a clinical stage vaccine company, today released its financial and operational results for the quarter ended March 31, 2014. Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies
Marketwire - Tue Apr 01, 7:06AM CDT
Immunovaccine Inc. ("Immunovaccine"
(TSX VENTURE: IMV) and Pfenex Inc. ("Pfenex" today announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses. Immunovaccine Announces 2013 Year-End Results
Marketwire - Mon Mar 17, 7:06AM CDT
Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its financial and operational results for the year ended December 31, 2013.
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Immunovaccine Inc names Dr Llew Keltner to board
M2 - Tue Jan 21, 4:13AM CST
Immunotherapy company Immunovaccine Inc (TSX VENTURE:IMV) reported on Monday the addition of Dr Llew Keltner, MD, PhD to its board of directors with immediate effect.
Llew Keltner, US Biotech Industry Adviser, Joins Board of Immunovaccine
Marketwire - Mon Jan 20, 7:08AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, has elected Llew Keltner, M.D., Ph.D. to its board of directors. The appointment is effective immediately. Immunovaccine Grants Stock Options
Marketwire - Mon Jan 20, 7:06AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that pursuant to terms and conditions of the Company's stock option plan, it has granted 1,731,500 stock options to employees, consultants, officers and directors. Employees and consultants were granted an aggregate of 457,500 options and officers and directors were granted an aggregate of 1,274,000 options. The options were granted on January 17, 2014 at an exercise price of $0.74. The options for the employees, consultants and directors will vest in three equal tranches at 6, 12, and 18 months from date of grant and the options for the officers will vest in three equal tranches, the first on the date of grant and the others on the first and second anniversary of the date of grant. All options are set to expire five years from the date of grant. Immunovaccine to Present at 6th Annual Biotech Showcase Conference
Marketwire - Thu Jan 09, 7:05AM CST
Immunovaccine Inc. ("Immunovaccine" or "IMV" or "the Company"
(TSX VENTURE: IMV), a clinical stage vaccine and immunotherapy company, today announced that the Company will present at the 6th Annual Biotech Showcase Conference. The conference will take place January 13-15, 2014 at the Parc 55 Wyndham San Francisco Union Square Hotel. 
(0)
(0)Scroll down for more posts ▼